Next-generation Vioxx could escape recall fallout, study suggests

WHITEHOUSE STATION, NJ: The Vioxx recall has not appeared to have hurt competitor drugs that stop pain in a similar fashion, and that could spell good news for Merck's next pain product, Arcoxia.

by Beth Herskovits

Sign in to continue

Sign in

Sign in

Trouble signing in?

Reset password: Click here

US and Asia
subscriptions@prweek.com
+001 (800) 558-1708

UK & Europe
support@prweek.com
+44 (0)20 8267 8121

Register

Don't have an account? Complete easy registration and receive:

  • Limited Article Views (Excludes Subscriber Only Content)
  • Select Newsletters (Excludes Subscriber Only Bulletins)

Register Now

Register

FREE

  • Limited free articles a month
  • Limited number of free email bulletins

Register Now

Subscribe

To receive full access to PRWeek's content subscribe today and receive:

  • Unlimited access to PRWeek content
  • Daily Breakfast Briefing
  • Breaking News Alerts
  • Weekly Online Edition
  • Agency Business Report
  • Weekender Edition
  • PRWeek Magazine
  • Full Archive Access

Subscribe Options

Start your free trial 

Enjoy these subscriber-exclusive benefits:

  • Unrestricted individual access to prweek.com
  • Breaking news and industry updates via PRWeek Daily News bulletin
  • Exclusive access to Power Book and Top 150 UK Agency Business Report

Join today

Need to activate your subscription?

Domain/Group Subscriptions
Click here >>

Individual Subscriptions
Click here >>

Need to activate your Subscription

Company Wide Subscriptions
Click here >>

 UK Individual Subscribers
Click here >>